MarketBeat
09 Aug 2026, 04:04 UTC · 9w ago
Revvity Q2 Earnings Call Highlights
Impact · against what's priced in
Revvity's raised guidance and strong AI-driven instrument demand provide a positive catalyst for growth expectations. While a significant portion of the earnings beat was non-recurring, the structural shift toward 'lab-in-the-loop' AI workflows and a multi-year high backlog suggest a tangible recovery in life sciences.
- RVTY+0.50
No priced-in read yet
- In context
The company raised its full-year outlook and reported a backlog at its strongest level in three to four years, supported by double-digit growth in high-content screening instruments for AI-driven drug discovery.
Read from the article alone
